Assurex Health Ltd, a subsidiary of Myriad Neuroscience, Toronto, ON, M5T 1L8, Canada.
Myriad Genetics Inc., Salt Lake City, UT 84108, USA.
Pharmacogenomics. 2020 Jun;21(8):521-531. doi: 10.2217/pgs-2020-0012. Epub 2020 Apr 17.
Evaluate the cost-effectiveness of combinatorial pharmacogenomic (PGx) testing, versus treatment as usual (TAU), to guide treatment for patients with depression, from the Canadian public healthcare system perspective. Clinical and economic data associated with depression were extracted from published literature. Clinical (quality-adjusted life years; QALYs) and economic (incremental cost-effectiveness ratio) outcomes were modeled using combinatorial PGx and TAU treatment strategies across a 5-year time horizon. With the combinatorial PGx strategy to guide treatment, patients were projected to gain 0.14-0.19 QALYs versus TAU. Accounting for test price, combinatorial PGx saved CAD $1,687-$3,056 versus TAU. Incremental cost-effectiveness ratios ranged from -$11,861 to -$16,124/QALY gained. Combinatorial PGx testing was more efficacious and less costly compared with the TAU for depression.
从加拿大公共医疗保健系统的角度出发，评估组合式药物基因组学 (PGx) 检测与常规治疗 (TAU) 相比，用于指导抑郁症患者治疗的成本效益。从已发表的文献中提取了与抑郁症相关的临床和经济数据。使用组合式 PGx 和 TAU 治疗策略，在 5 年的时间范围内对临床（质量调整生命年；QALYs）和经济（增量成本效益比）结果进行建模。与 TAU 相比，采用组合式 PGx 策略指导治疗，预计患者将获得 0.14-0.19 个 QALY。考虑到测试价格，与 TAU 相比，组合式 PGx 可节省 CAD$1687-CAD$3056。增量成本效益比范围为 -$11861 至 -$16124/QALY 增加。与 TAU 相比，组合式 PGx 检测在治疗抑郁症方面更有效且成本更低。
